Alnylam To Collaborate With United States Army On RNAi Therapeutics For Biodefense Threats

Published: Apr 12, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 12, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement, Alnylam will collaborate with USAMRIID to discover RNAi therapeutics targeting viral organisms, including hemorrhagic fever viruses, which pose a serious biological threat to the military and public health of the United States.

Back to news